Isolation, behavioral changes and low seroprevalence of SARS-CoV-2 antibodies in patients with Systemic Lupus Erythematosus or Rheumatoid arthritis.
Christian AmmitzbøllJakob Bøgh AndersenSigne Risbøl VilsClara Elbaek MistegaardSusan MikkelsenChristian ErikstrupMarianne Kragh ThomsenEllen-Margrethe HaugeAnne TroldborgPublished in: Arthritis care & research (2021)
Low seroprevalence in patients with CRDs indicates successful mitigation of exposure to SARS-CoV-2. However, this appears to occur at the expense of physical activity, experience of increased pain, disease activity, and symptoms of depression. There is a need for care providers to be aware of these negative side-effects and for further studies to investigate the possible long-term consequences.
Keyphrases
- disease activity
- sars cov
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- physical activity
- ankylosing spondylitis
- sleep quality
- respiratory syndrome coronavirus
- juvenile idiopathic arthritis
- chronic pain
- pain management
- healthcare
- climate change
- depressive symptoms
- palliative care
- body mass index
- neuropathic pain
- interstitial lung disease
- quality improvement
- spinal cord injury
- systemic sclerosis
- coronavirus disease